2201066-53-5Relevant academic research and scientific papers
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion
Konteatis, Zenon,Travins, Jeremy,Gross, Stefan,Marjon, Katya,Barnett, Amelia,Mandley, Everton,Nicolay, Brandon,Nagaraja, Raj,Chen, Yue,Sun, Yabo,Liu, Zhixiao,Yu, Jie,Ye, Zhixiong,Jiang, Fan,Wei, Wentao,Fang, Cheng,Gao, Yi,Kalev, Peter,Hyer, Marc L.,Delabarre, Byron,Jin, Lei,Padyana, Anil K.,Dang, Lenny,Murtie, Joshua,Biller, Scott A.,Sui, Zhihua,Marks, Kevin M.
, p. 4430 - 4449 (2021)
The metabolic enzyme methionine adenosyltransferase 2A (MAT2A) was recently implicated as a synthetic lethal target in cancers with deletion of the methylthioadenosine phosphorylase (MTAP) gene, which is adjacent to the CDKN2A tumor suppressor and codelet
